HIGHLIGHTS
- who: Daniela Romina Montagna from the Laboratory of Experimental Oncology, Instituto Experimental, Argentina have published the research: Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor, in the Journal: (JOURNAL)
- what: The authors have evaluated firstly the efficacy of ICI (as well as classical antitumor vaccines) in function of target immunogenicity. To strengthen that weak response and turn it into an inhibitory one, the authors propose to combine ICI-therapy with two different but complementary strategies, the use of meta-tyrosine and that of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.